

Macro Ghost on Youtube
36.1K posts

@Deepvalue69420
instagram: @robs_life2025






$IBRX The pressure on the FDA is getting louder. Patients, advocates, doctors, and now more oncology voices are all saying the same thing: approve Anktiva for papillary bladder cancer. This is not about a stock headline anymore. It is about patients running out of options while a treatment with real potential sits waiting. Everyone is doing their part now. FDA needs to act.










Looking forward to presenting at AUA soon. Chemotherapy induces lymphopenia with increases in recurrence rates in bladder cancer, while BCG is an established immunotherapy. We need to fix the 14 year BCG shortage situation and it’s not through an alternative of more chemo which even results in fatality from the chemo. It’s to find alternative BCG. Stay tuned.




‼️Market frenzy has reached unprecedented levels: The ratio of US momentum stocks to minimum volatility stocks has surged to a record high. This is also a 5 standard deviation overshoot above the long-term trend, the most extreme reading in over 25 years of data. In plain terms, momentum stocks, fast-moving, high-growth names like NVIDIA, have never been this expensive relative to low-volatility defensive stocks like utilities and consumer staples. Every single time this ratio has spiked, the unwind has been violent. Will history repeat itself?




